Call for more transparency in manufacturers declarations on serum indices: On behalf of the Working Group for Preanalytical Phase (WG-PRE), European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Clinica Chimica Acta

Volumn 484, Issue , 2018, Pages 328-332

  von Meyer, Alexander ^a   Cadamuro, Janne ^b   Lippi, Giuseppe ^c   Simundic, Ana Maria ^d  

^a Kliniken Nordoberpfalz AG   (Germany)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

^d University Hospital Sveti Duh   (Croatia)

Author keywords

Hemolysis; Icterus; Interference; Lipemia; Preanalytical phase; Serum indices

Indexed keywords

BILIRUBIN; HEMOGLOBIN; LIPID;

ARTIFACT; BLOOD; CLINICAL CHEMISTRY; HUMAN; MEDICAL TECHNOLOGY; PRE-ANALYTICAL PHASE; PROCEDURES; STANDARDS;

ARTIFACTS; BILIRUBIN; CHEMISTRY, CLINICAL; HEMOGLOBINS; HUMANS; LIPIDS; MEDICAL LABORATORY SCIENCE; PRE-ANALYTICAL PHASE;

EID: 85045079881     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2018.03.043     Document Type: Note

References (34)

1. Plebani, M., Errors in laboratory medicine and patient safety: the road ahead. Clin. Chem. Lab. Med. 45:6 (2007), 700–707.
2. Lippi, G. et al., Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin. Chem. Lab. Med. 46:6 (2008), 764–772.
3. Forsman, R.W., Why is the laboratory an afterthought for managed care organizations?. Clin. Chem. 42:5 (1996), 813–816.
4. Rohr, U.-P. et al., The value of in vitro diagnostic testing in medical practice: a status report. PLoS One, 11(3), 2016, e0149856.
5. Ryder, K.W., Glick, M.R., Erroneous laboratory results from hemolyzed, icteric, and lipemic specimens. Clin. Chem. 39:1 (1993), 175–176.
6. Hallworth, M.J., The ‘70% claim’: what is the evidence base?. Ann. Clin. Biochem. 48:Pt 6 (2011), 487–488.
7. Simundic, A.M. et al., Hemolysis detection and management of hemolyzed specimens. Biochem. Med. 20:2 (2010), 154–159.
8. Nagant, C., Rozen, L., Demulder, A., HIL interferences on three hemostasis analyzers and contribution of a preanalytical module for routine coagulation assays. Clin. Lab. 62:10 (2016), 1979–1987.
9. Clinical and Laboratory Standards Institute, C56-A:2012 Hemolysis, Icterus and Lipemia/Turbidity Indices as Indicators of Interference in Clinical Laboratory Analysis; Approved Guideline. 2012, Clinical and Laboratory Standards Institute, Wayne, PA.
10. Ceriotti, F. et al., Criteria for assigning laboratory measurands to models for analytical performance specifications defined in the 1st EFLM Strategic Conference. Clin. Chem. Lab. Med. 55:2 (2017), 189–194.
11. Lippi, G. et al., Influence of hemolysis on routine clinical chemistry testing. Clin. Chem. Lab. Med. 44:3 (2006), 311–316.
12. Lippi, G. et al., Interference of blood cell lysis on routine coagulation testing. Arch. Pathol. Lab. Med. 130:2 (2006), 181–184.
13. Sciacovelli, L. et al., Defining a roadmap for harmonizing quality indicators in laboratory medicine: a consensus statement on behalf of the IFCC working group “laboratory error and patient safety” and EFLM task and finish group “performance specifications for the extra-analytical phases”. Clin. Chem. Lab. Med. 55:10 (2017), 1478–1488.
14. Bundesärztekammer, Richtlinie der Bundesärztekammer zur Qualitätssicherung laboratoriumsmedizinischer Untersuchungen – Rili-BÄK. Deutsches Ärzteblatt 111:38 (2014), A1583–A1618.
15. Sciacovelli, L. et al., Quality indicators in laboratory medicine: the status of the progress of IFCC working group “laboratory errors and patient safety” project. Clin. Chem. Lab. Med. 55:3 (2017), 348–357.
16. Plebani, M. et al., The use of extra-analytical phase quality indicators by clinical laboratories: the results of an international survey. Clin. Chem. Lab. Med. 54:11 (2016), e315–e317.
17. Cadamuro, J. et al., Hemolysis rates in blood samples: differences between blood collected by clinicians and nurses and the effect of phlebotomy training. Clin. Chem. Lab. Med. 54:12 (2016), 1987–1992.
18. Petinos, P., Gay, S., Badrick, T., Variation in laboratory reporting of haemolysis - a need for harmonisation. Clin. Biochem. Rev. 36:4 (2015), 133–137.
19. Jones, G.R., The role of EQA in harmonization in laboratory medicine - a global effort. Biochem Med (Zagreb) 27:1 (2017), 23–29.
20. Dolci, A., Panteghini, M., Harmonization of automated hemolysis index assessment and use: is it possible?. Clin. Chim. Acta 432 (2014), 38–43.
21. Clinical and Laboratory Standards Institute, Interference Testing in Clinical Chemistry; Approved Guideline. second ed., 2005, Clinical and Laboratory Standards Institute, Wayne, PA.
22. Cadamuro, J. et al., A pragmatic approach to sample acceptance and rejection. Clin. Biochem. 50:10–11 (2017), 579–581.
23. Fernandez, P. et al., Harmonization in hemolysis detection and prevention. A working group of the Catalonian health institute (ICS) experience. Clin. Chem. Lab. Med. 52:11 (2014), 1557–1568.
24. Nikolac, N. et al., Heterogeneity of manufacturers’ declarations for lipemia interference—an urgent call for standardization. Clin. Chim. Acta 426 (2013), 33–40.
25. Brunori, P. et al., Evaluation of bilirubin concentration in hemolysed samples, is it really impossible? The altitude-curve cartography approach to interfered assays. Clin. Chim. Acta 412:9–10 (2011), 774–777.
26. Unger, J., Filippi, G., Patsch, W., Measurements of free hemoglobin and hemolysis index: EDTA- or lithium-heparinate plasma?. Clin. Chem. 53:9 (2007), 1717–1718.
27. Lippi, G. et al., Multicenter evaluation of the hemolysis index in automated clinical chemistry systems. Clin. Chem. Lab. Med. 47:8 (2009), 934–939.
28. Ji, J.Z., Meng, Q.H., Evaluation of the interference of hemoglobin, bilirubin, and lipids on Roche Cobas 6000 assays. Clin. Chim. Acta 412:17–18 (2011), 1550–1553.
29. Sandberg, S. et al., Defining analytical performance specifications: consensus statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine. Clin. Chem. Lab. Med. 53:6 (2015), 833–835.
30. Thomas, M. et al., A pre-analytical EQA scheme for sample integrity: A WEQAS study to monitor the effectiveness of serum indices. 3rd EFLM-BD European Conference on Preanalytical Phase, 2015 (Porto, Lisboa).
31. Steen, G. et al., Evaluation of the interference due to haemoglobin, bilirubin and lipids on Immulite 2500 assays: a practical approach. Ann. Clin. Biochem. 48:Pt 2 (2011), 170–175.
32. Lippi, G. et al., Reference range of hemolysis index in serum and lithium-heparin plasma measured with two analytical platforms in a population of unselected outpatients. Clin. Chim. Acta 429 (2014), 143–146.
33. Diagnostics, R., Serum-Indizes: Die Reduzierung klinischer Fehler in der Labormedizin. 2010, Roche Diagnostics Deutschland GmbH.
34. Lippi, G., Cadamuro, J., von Meyer, A., Simundic, A.M., Local quality assurance of serum or plasma (HIL) indices. Clin. Biochem., 2018 Mar 3, 10.1016/j.clinbiochem.2018.02.018 (Epub ahead of print).